We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current RGLS market cap is 108.08M. The company's latest EPS is USD -0.4586 and P/E is -3.53.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.13M | -8.3M | -8.83M | -12.26M | -15.21M |
| Net Income | -7.82M | -8.06M | -8.47M | -11.04M | -14.06M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.83M | 10.01M | 0 | 0 | 0 |
| Operating Income | -16.83M | -14.16M | -27.82M | -28.24M | -31.11M |
| Net Income | -18.59M | -15.73M | -27.81M | -28.32M | -30.04M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 37.75M | 30.75M | 114.14M | 104.12M | 93.76M |
| Total Liabilities | 9.49M | 9.56M | 6.55M | 5.94M | 6.96M |
| Total Equity | 28.26M | 21.19M | 107.59M | 98.18M | 86.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 42.08M | 37.6M | 68.45M | 46.72M | 30.75M |
| Total Liabilities | 22.07M | 11.58M | 13.5M | 13.43M | 9.56M |
| Total Equity | 20.02M | 26.03M | 54.96M | 33.29M | 21.19M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -20.64M | -26.77M | -8.74M | -20.38M | -29.83M |
| Investing | 9.56M | 14.49M | -78.54M | -78.63M | -59.98M |
| Financing | 12.69M | 11.82M | 93.11M | 92.36M | 92.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -19.82M | -12.54M | -24.13M | -25.53M | -26.77M |
| Investing | 74k | -11k | -251k | -15.12M | 14.49M |
| Financing | 39.93M | 9.51M | 53.74M | 4.49M | 11.82M |
| Market Cap | 108.08M |
| Price to Earnings Ratio | -3.53 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 4.46 |
| Price to Book Ratio | 5.01 |
| Dividend Yield | - |
| Shares Outstanding | 65.5M |
| Average Volume (1 week) | 318.4k |
| Average Volume (1 Month) | 260.41k |
| 52 Week Change | 22.22% |
| 52 Week High | 3.78 |
| 52 Week Low | 1.08 |
| Spread (Intraday) | 0.14 (8.38%) |
| Company Name | Regulus Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.regulusrx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
